

# Michael B Atkins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9049169/publications.pdf>

Version: 2024-02-01

228  
papers

54,255  
citations

10986

71  
h-index

2078

204  
g-index

233  
all docs

233  
docs citations

233  
times ranked

44956  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	27.0	10,727
2	Final Version of 2009 AJCC Melanoma Staging and Classification. <i>Journal of Clinical Oncology</i> , 2009, 27, 6199-6206.	1.6	4,126
3	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	1.6	2,691
4	Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. <i>Journal of Clinical Oncology</i> , 2001, 19, 3622-3634.	1.6	2,394
5	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
6	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	1.6	2,015
7	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.	27.0	1,824
8	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. <i>Journal of Clinical Oncology</i> , 1999, 17, 2105-2105.	1.6	1,810
9	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
10	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5794-5799.	1.6	1,751
11	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	10.7	1,274
12	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	27.0	983
13	Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 909-918.	1.6	948
14	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	30.7	900
15	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	13.7	778
16	Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 133-141.	1.6	746
17	Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 527-534.	1.6	634
18	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	1.6	580

#	ARTICLE	IF	CITATIONS
19	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 13.75 BT / Overlock 10		529
20	Toxicities of Immunotherapy for the Practitioner. <i>Journal of Clinical Oncology</i> , 2015, 33, 2092-2099.	1.6	521
21	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 632-642.	3.4	512
22	Resistance to targeted therapy in renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2009, 10, 992-1000.	10.7	496
23	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	10.7	466
24	Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3714-3721.	7.0	401
25	A new American Joint Committee on Cancer staging system for cutaneous melanoma. <i>Cancer</i> , 2000, 88, 1484-1491.	4.1	389
26	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	7.1	388
27	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	1.6	385
28	PD-1 as a potential target in cancer therapy. <i>Cancer Medicine</i> , 2013, 2, 662-673.	2.8	369
29	Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2101-2107.	1.6	337
30	Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells. <i>New England Journal of Medicine</i> , 1988, 318, 1557-1563.	27.0	333
31	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 405-415.	10.7	305
32	Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 5748-5754.	1.6	292
33	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. <i>International Immunology</i> , 2015, 27, 39-46.	4.0	286
34	Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2018, 70, 127-137.	7.7	276
35	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	16.8	262
36	Intratatumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. <i>Cancer Immunology Research</i> , 2016, 4, 419-430.	3.4	247

#	ARTICLE	IF	CITATIONS
37	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	1.6	244
38	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1158-1164.	3.4	237
39	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 451-460.	10.7	228
40	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	10.7	211
41	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 373-379.	1.6	199
42	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. <i>Cancer</i> , 2014, 120, 1695-1701.	4.1	195
43	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	1.6	190
44	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
45	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 588-598.	27.6	177
46	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. <i>Clinical Cancer Research</i> , 2011, 17, 5443-5450.	7.0	164
47	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	1.6	164
48	Checkpoint inhibitor immunotherapy in kidney cancer. <i>Nature Reviews Urology</i> , 2020, 17, 137-150.	3.8	162
49	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	10.7	160
50	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	1.6	156
51	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	1.6	145
52	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. , 2018, 6, 9.		141
53	Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6342S-6346S.	7.0	133
54	The High-Dose Aldesleukin “Select”-Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 561-568.	7.0	133

#	ARTICLE	IF	CITATIONS
55	Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 632-646.	0.8	132
56	High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. , 2014, 2, 26.		130
57	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	10.7	129
58	The New Melanoma Staging System. <i>Cancer Control</i> , 2002, 9, 9-15.	1.8	123
59	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	1.6	121
60	Interleukin-2: Clinical applications. <i>Seminars in Oncology</i> , 2002, 29, 12-17.	2.2	116
61	Does Arterial Spin-labeling MR Imagingâ€“measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?. <i>Radiology</i> , 2009, 251, 731-742.	7.3	111
62	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 66-72.	2.4	111
63	Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20.	5.5	111
64	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9507-9507.	1.6	106
65	Randomized, Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Groupâ€“American College of Radiology Imaging Network Cancer Research Group (E4697). <i>Journal of Clinical Oncology</i> , 2014, 32, 3771-3778.	1.6	101
66	Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanomaâ€“An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3771-3778.	1.6	99
67	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
68	DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trialâ€“ECOG-ACRIN EA6134.. <i>Journal of Clinical Oncology</i> , 2021, 39, 356154-356154.	1.6	90
69	Patient Preferences for Adjuvant Interferon Alfa-2b Treatment. <i>Journal of Clinical Oncology</i> , 2001, 19, 812-823.	1.6	85
70	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4500-4500.	1.6	85
71	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	12.8	84
72	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	1.6	83

#	ARTICLE	IF	CITATIONS
73	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv414.	6.3	81
74	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.	7.0	80
75	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
76	YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells. <i>Developmental Cell</i> , 2019, 49, 425-443.e9.	7.0	78
77	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4500-4500.	1.6	78
78	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. <i>Cancer</i> , 2008, 113, 2139-2145.	4.1	77
79	Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 95, 24-31.	4.7	75
80	BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinomaâ€”A Trial of the ECOGâ€”ACRIN Cancer Research Group (E2804). <i>Journal of Clinical Oncology</i> , 2015, 33, 2384-2391.	1.6	75
81	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	7.1	75
82	Everolimus. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 535-536.	46.4	74
83	Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. <i>Journal of Immunotherapy</i> , 2018, 41, 332-335.	2.4	68
84	Prognostic and predictive markers for the new immunotherapies. <i>Oncology</i> , 2014, 28 Suppl 3, 39-48.	0.5	68
85	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1925-1934.	7.0	67
86	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	1.2	66
87	Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression. <i>PLoS ONE</i> , 2011, 6, e19144.	2.5	64
88	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poorâ€”risk metastatic renal cell carcinoma. <i>Cancer</i> , 2015, 121, 3435-3443.	4.1	64
89	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	1.9	64
90	A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. <i>Clinical Cancer Research</i> , 2002, 8, 3075-81.	7.0	64

#	ARTICLE	IF	CITATIONS
91	Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2793-2802.	4.1	63
92	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
93	Dissecting the treatment-naïve ecosystem of human melanoma brain metastasis. <i>Cell</i> , 2022, 185, 2591-2608.e30.	28.9	62
94	Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3088-3094.	1.6	61
95	Strategies for improving the management of immune-related adverse events. , 2020, 8, e001754.		60
96	Evolving impact of long-term survival results on metastatic melanoma treatment. , 2020, 8, e000948.		59
97	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. <i>Oncologist</i> , 2018, 23, 540-555.	3.7	57
98	Indoor Tanning Dependence in Young Adult Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1636-1643.	2.5	56
99	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4505-4505.	1.6	55
100	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
101	Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibitionâ€”A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3350-3358.	1.6	52
102	Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1,) Tj ETQq0 0 0 rgBT /Overlock 10 T of <i>Clinical Oncology</i> , 2014, 32, LBA9003-LBA9003.	1.6	51
103	Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. <i>Clinical Cancer Research</i> , 2015, 21, 4048-4054.	7.0	50
104	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5001-5001.	1.6	50
105	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3431-3438.	1.6	49
106	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	7.0	49
107	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , 2018, 24, 1805-1815.	7.0	45
108	Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. <i>Cancer</i> , 2016, 122, 124-130.	4.1	43

#	ARTICLE	IF	CITATIONS
109	The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. <i>Oncotarget</i> , 2017, 8, 12576-12595.	1.8	43
110	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.. <i>Journal of Clinical Oncology</i> , 2019, 37, 546-546.	1.6	42
111	Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. <i>Gastroenterology</i> , 2021, 160, 1359-1372.e13.	1.3	41
112	The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma. <i>Translational Oncology</i> , 2014, 7, 188-195.	3.7	40
113	Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. , 2019, 7, 61.		40
114	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	1.6	40
115	Innovations and Challenges in Renal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6277S-6281S.	7.0	38
116	What's new in melanoma? Combination!. <i>Journal of Translational Medicine</i> , 2015, 13, 213.	4.4	38
117	Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference: Fig. 1.. <i>Clinical Cancer Research</i> , 2007, 13, 667s-670s.	7.0	36
118	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 820-824.	4.9	36
119	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 527-541.	3.3	36
120	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4504-4504.	1.6	35
121	Tumor Necrosis on Magnetic Resonance Imaging Correlates With Aggressive Histology and Disease Progression in Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 55-62.	1.9	34
122	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	7.0	34
123	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.	1.6	33
124	Treatment selection for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2327-2333.	4.1	32
125	Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis. <i>ACG Case Reports Journal</i> , 2018, 5, e17.	0.4	30
126	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4512-4512.	1.6	30

#	ARTICLE	IF	CITATIONS
127	Management of metastatic cutaneous melanoma: updates in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985166.	3.2	29
128	Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2019, 11, 617-629.	2.0	29
129	Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?. <i>Clinical Cancer Research</i> , 2014, 20, 2838-2845.	7.0	28
130	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	7.0	27
131	New Agents and New Targets for Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e222-e227.	3.8	26
132	A case of checkpoint inhibitor-induced celiac disease. , 2019, 7, 203.		25
133	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	7.0	25
134	Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. <i>Cancer</i> , 2009, 115, 2247-2251.	4.1	24
135	Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. <i>Medical Oncology</i> , 2009, 26, 18-22.	2.5	24
136	Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. <i>Seminars in Oncology</i> , 2015, 42, S12-S19.	2.2	24
137	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. <i>Cancer Medicine</i> , 2017, 6, 1904-1914.	2.8	24
138	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. <i>Immunotherapy</i> , 2019, 11, 283-295.	2.0	24
139	Ipilimumab associated colitis: An IpiColitis case series at MedStar Georgetown University Hospital. <i>World Journal of Gastroenterology</i> , 2015, 21, 4373.	3.3	24
140	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (NCC-RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4569-4569.	1.6	23
141	Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8569-8569.	1.6	21
142	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. <i>Oncotarget</i> , 0, 7, 41857-41869.	1.8	21
143	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	1.9	20
144	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	7.0	20

#	ARTICLE	IF	CITATIONS
145	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	1.9	20
146	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3557-3565.	7.0	19
147	Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon Response. <i>Cancer Research</i> , 2021, 81, 3607-3620.	0.9	19
148	Characterization of tumor mutation load (TML) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11517-11517.	1.6	19
149	Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma. , 2015, 3, .		18
150	Cancer Immunotherapy: Past Progress and Future Directions. <i>Seminars in Oncology</i> , 2015, 42, 518-522.	2.2	17
151	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. <i>European Journal of Cancer</i> , 2021, 145, 1-10.	2.8	17
152	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3009-3009.	1.6	17
153	Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. , 2021, 7, .		16
154	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
155	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). <i>Melanoma Research</i> , 2021, 31, 67-75.	1.2	15
156	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4594-TPS4594.	1.6	15
157	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 427-439.	1.9	15
158	Management of advanced renal cancer. <i>Kidney International</i> , 2005, 67, 2069-2082.	5.2	14
159	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 6098-6106.	7.0	14
160	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naïve patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. <i>Quality of Life Research</i> , 2019, 28, 109-119.	3.1	14
161	Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8504-8504.	1.6	14
162	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743.		14

#	ARTICLE	IF	CITATIONS
163	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5598-5608.	7.0	13
164	Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. <i>Radiology</i> , 2021, 298, 332-340.	7.3	13
165	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 454-489.	329.8	13
166	Choice of first-line therapy in metastatic melanoma. <i>Cancer</i> , 2019, 125, 666-669.	4.1	12
167	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e306-e312.	1.9	12
168	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	1.6	12
169	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
170	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	7.0	12
171	Phase 2 Study of Bevacizumab and Temezolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 304-313.e6.	1.9	11
172	Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9554-9554.	1.6	11
173	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. <i>Cancers</i> , 2022, 14, 644.	3.7	11
174	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e505-e514.	3.8	10
175	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. <i>Immunotherapy</i> , 2020, 12, 37-51.	2.0	10
176	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9545-9545.	1.6	10
177	Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1873-1877.	1.6	9
178	Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. <i>Melanoma Research</i> , 2019, 29, 70-76.	1.2	9
179	Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies " CPIT-001 Trial. <i>Blood</i> , 2018, 132, 256-256.	1.4	9
180	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4505-4505.	1.6	9

#	ARTICLE	IF	CITATIONS
181	Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, e15074-e15074.	1.6	9
182	Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers, 2021, 13, 6109.	3.7	9
183	Automated Identification of Patients With Immune-Related Adverse Events From Clinical Notes Using Word Embedding and Machine Learning. JCO Clinical Cancer Informatics, 2021, 5, 541-549.	2.1	8
184	PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma. , 2021, 9, e002955.		8
185	Support for indoor tanning policies among young adult women who indoor tan. Translational Behavioral Medicine, 2016, 6, 613-621.	2.4	7
186	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. Journal of Clinical Oncology, 2012, 30, CRA2509-CRA2509.	1.6	7
187	Treatment of Melanoma CNS Metastases. Cancer Treatment and Research, 2016, 167, 263-279.	0.5	6
188	Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, 4500-4500.	1.6	6
189	Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. Journal of Clinical Oncology, 2017, 35, 9522-9522.	1.6	6
190	Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). Expert Opinion on Emerging Drugs, 2016, 21, 243-254.	2.4	5
191	Genetic Associations with Indoor Tanning Addiction among non-Hispanic White Young Adult Women. Annals of Behavioral Medicine, 2020, 54, 1-9.	2.9	5
192	Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities. Journal of Immunotherapy, 2021, 44, 198-203.	2.4	5
193	Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study.. Journal of Clinical Oncology, 2012, 30, 4606-4606.	1.6	5
194	The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 800-807.e1.	4.9	5
195	Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for BRAF-mutant melanoma: a case report. Melanoma Management, 2015, 2, 115-120.	0.5	4
196	A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor. Immunotherapy, 2020, 12, 861-867.	2.0	4
197	Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.. Journal of Clinical Oncology, 2018, 36, 9538-9538.	1.6	4
198	Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy. Future Oncology, 2022, , .	2.4	4

#	ARTICLE	IF	CITATIONS
199	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
200	Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.. Journal of Clinical Oncology, 2012, 30, CRA2509-CRA2509.	1.6	3
201	Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.. Journal of Clinical Oncology, 2018, 36, e21609-e21609.	1.6	3
202	Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4515-4515.	1.6	3
203	New Options and New Questions: How to Select and Sequence Therapies for Patients with Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 524-530.	3.8	3
204	Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. Journal of Immunotherapy, 2007, 30, 577-590.	2.4	2
205	Correlates of Sun Safety Practices in a Racially and Ethnically Diverse Sample of Adolescents: Implications for Skin Cancer Prevention Interventions. Pediatric Dermatology, 2015, 32, e288-90.	0.9	2
206	Predicting early relapse in patients with BRAF <sup>V600E</sup> melanoma with a highly sensitive blood BRAF assay.. Journal of Clinical Oncology, 2012, 30, 8516-8516.	1.6	2
207	Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, TPS4600-TPS4600.	1.6	2
208	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. Journal of Clinical Oncology, 2018, 36, 619-619.	1.6	2
209	Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.. Journal of Clinical Oncology, 2019, 37, 9533-9533.	1.6	2
210	Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. Melanoma Research, 2022, 32, 35-44.	1.2	2
211	Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2018, 132, 3421-3421.	1.4	1
212	CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma.. Journal of Clinical Oncology, 2012, 30, 8527-8527.	1.6	1
213	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 4573-4573.	1.6	1
214	Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers, 2022, 14, 1505.	3.7	1
215	Algorithm for the management of metastatic cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 32.	1.2	1
216	Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. Expert Review of Anticancer Therapy, 2022, 22, 565-574.	2.4	1

#	ARTICLE	IF	CITATIONS
217	Immunotherapy comes of age: overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer. Expert Opinion on Biological Therapy, 2007, 7, 419-422.	3.1	0
218	An Analysis of 1 year versus 3 month alpha-Interferon Treatment in Patients with Melanoma Stages IIB, IIC, and IIIA. FASEB Journal, 2010, 24, 954-5.	0.5	0
219	Genetic polymorphisms influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents.. Journal of Clinical Oncology, 2012, 30, 4635-4635.	1.6	0
220	Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition.. Journal of Clinical Oncology, 2012, 30, 4543-4543.	1.6	0
221	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. Journal of Clinical Oncology, 2017, 35, 4576-4576.	1.6	0
222	Cytokines (IL-2, IFN GM-CSF etc) Melanoma. , 2019, , 1-31.		0
223	Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence. Blood, 2018, 132, 3443-3443.	1.4	0
224	Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma. , 2020, , 1109-1140.		0
225	Identification of Patients with Immune-related Adverse Events from Clinical Notes using Machine Learning. , 2020, , .		0
226	The effect of recent drug approvals on translational research and drug development. Clinical Advances in Hematology and Oncology, 2007, 5, 285-7.	0.3	0
227	Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic. Journal of Oncology, 2022, 2022, 1-8.	1.3	0
228	Abstract 6130: Comprehensive genomic and transcriptomic profiling of acral lentiginous melanoma. Cancer Research, 2022, 82, 6130-6130.	0.9	0